[go: up one dir, main page]

AR093788A1 - Inmunoterapia con agentes de enlace - Google Patents

Inmunoterapia con agentes de enlace

Info

Publication number
AR093788A1
AR093788A1 ARP130104485A ARP130104485A AR093788A1 AR 093788 A1 AR093788 A1 AR 093788A1 AR P130104485 A ARP130104485 A AR P130104485A AR P130104485 A ARP130104485 A AR P130104485A AR 093788 A1 AR093788 A1 AR 093788A1
Authority
AR
Argentina
Prior art keywords
pvr
binding agents
variant
disclosed
extracellular domain
Prior art date
Application number
ARP130104485A
Other languages
English (en)
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of AR093788A1 publication Critical patent/AR093788A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan agentes de enlace que modulan la respuesta inmune. Los agentes de enlace pueden incluir receptores solubles, polipéptidos, y/o anticuerpos. También se divulgan métodos para utilizar los agentes de enlace para el tratamiento de enfermedades tales como el cáncer. Reivindicación 1: Un receptor soluble aislado que comprende una variante del receptor de poliovirus (PVR), en el que la variante de PVR comprende una o más sustituciones de aminoácidos en comparación con el PVR de tipo salvaje, y en el que la variante de PVR se une específicamente al dominio extracelular de TIGIT humana y no se une o se une débilmente al dominio extracelular de CD226 humano.
ARP130104485A 2012-12-04 2013-12-04 Inmunoterapia con agentes de enlace AR093788A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261733177P 2012-12-04 2012-12-04
US201361789268P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR093788A1 true AR093788A1 (es) 2015-06-24

Family

ID=50884135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104485A AR093788A1 (es) 2012-12-04 2013-12-04 Inmunoterapia con agentes de enlace

Country Status (17)

Country Link
US (3) US9327014B2 (es)
EP (1) EP2928483A4 (es)
JP (1) JP2016502554A (es)
KR (1) KR20150090919A (es)
CN (1) CN104902913A (es)
AR (1) AR093788A1 (es)
AU (1) AU2013355379B2 (es)
BR (1) BR112015013127A2 (es)
CA (1) CA2892831A1 (es)
HK (1) HK1210964A1 (es)
IL (1) IL239089A0 (es)
MX (1) MX2015006973A (es)
NZ (1) NZ709059A (es)
RU (1) RU2015123032A (es)
TW (1) TW201439115A (es)
WO (1) WO2014089169A2 (es)
ZA (1) ZA201504478B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2085096A3 (en) 2002-09-11 2009-08-12 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
JP5770624B2 (ja) 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
AU2013271515A1 (en) * 2012-06-06 2015-01-15 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the Hippo pathway and uses thereof
CN104902913A (zh) 2012-12-04 2015-09-09 昂科梅德制药有限公司 使用结合剂的免疫治疗
WO2015009856A2 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
KR20230085220A (ko) * 2013-08-22 2023-06-13 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 및 바이러스 감염을 치료하기 위한 면역수용체 조절
WO2016011264A1 (en) * 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
CR20170060A (es) * 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
MX2017007744A (es) 2014-12-23 2017-09-05 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN108290936B (zh) 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
DK3353210T3 (da) 2015-09-25 2025-01-06 Hoffmann La Roche Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
WO2017059095A1 (en) 2015-10-01 2017-04-06 Potenza Therapeutics, Inc. Anti-tigit antigen-binding proteins and methods of use thereof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
IL261200B2 (en) 2016-03-01 2023-03-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific for the human poliovirus receptor
TWI752012B (zh) 2016-03-04 2022-01-11 美商Ｊｎ生物科學有限責任公司 針對tigit之抗體
CN107267454A (zh) * 2016-04-07 2017-10-20 北京京蒙高科干细胞技术有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
EP3443000A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
CN109414023A (zh) * 2016-06-29 2019-03-01 杜克大学 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) * 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2018041120A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018075978A1 (en) * 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
CN110662758A (zh) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
BR112019022009A2 (pt) 2017-04-21 2020-05-12 Sillajen, Inc. Terapia de combinação de vírus vaccinia oncolítico e inibidor de ponto de verificação
WO2019030377A1 (en) * 2017-08-11 2019-02-14 Blink Biomedical Sas CD96 BINDING AGENTS AS IMMUNOMODULATORS
CN111801347A (zh) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
AU2019264965A1 (en) 2018-05-09 2020-11-19 Nectin Therapeutics Ltd. Antibodies specific to human Nectin4
EP3823673A4 (en) 2018-07-20 2022-05-11 Surface Oncology, Inc. ANTI-CD112R COMPOSITIONS AND METHODS
TW202023625A (zh) 2018-08-23 2020-07-01 美商西雅圖遺傳學公司 抗tigit抗體
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CN110157686B (zh) * 2019-05-22 2022-06-21 南京惟亚德生物医药有限公司 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
CN112625130B (zh) 2019-09-24 2023-08-29 财团法人工业技术研究院 抗-tigit抗体及使用之方法
KR20220070011A (ko) 2019-09-27 2022-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 항원 결합 단백질
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US20240279342A1 (en) * 2019-11-15 2024-08-22 Surface Oncology, Inc. Compositions and methods for immunotherapy
CN114507284B (zh) * 2020-05-09 2023-05-26 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2025019828A1 (en) * 2023-07-20 2025-01-23 The General Hospital Corporation Chimeric inhibitory signaling modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CN1547617A (zh) 2001-06-25 2004-11-17 2 肿瘤学药物革新
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2242762B1 (en) 2008-01-18 2015-12-16 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5770624B2 (ja) * 2008-04-09 2015-08-26 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN104902913A (zh) 2012-12-04 2015-09-09 昂科梅德制药有限公司 使用结合剂的免疫治疗

Also Published As

Publication number Publication date
EP2928483A2 (en) 2015-10-14
WO2014089169A4 (en) 2014-09-12
CA2892831A1 (en) 2014-06-12
US20140186380A1 (en) 2014-07-03
BR112015013127A2 (pt) 2017-09-26
HK1210964A1 (en) 2016-05-13
US9833500B2 (en) 2017-12-05
US20160346368A1 (en) 2016-12-01
US20180214526A1 (en) 2018-08-02
NZ709059A (en) 2016-11-25
KR20150090919A (ko) 2015-08-06
WO2014089169A3 (en) 2014-08-07
TW201439115A (zh) 2014-10-16
MX2015006973A (es) 2015-09-28
JP2016502554A (ja) 2016-01-28
ZA201504478B (en) 2016-09-28
AU2013355379A1 (en) 2015-07-02
EP2928483A4 (en) 2016-06-08
IL239089A0 (en) 2015-07-30
RU2015123032A (ru) 2017-01-11
CN104902913A (zh) 2015-09-09
US9327014B2 (en) 2016-05-03
WO2014089169A2 (en) 2014-06-12
AU2013355379B2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
AR093788A1 (es) Inmunoterapia con agentes de enlace
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
BR112016022841A2 (pt) cadeia j modificada
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MX2020003512A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EA201490677A1 (ru) Связывающие антиген cd27l белки
PH12016501366A1 (en) Novel anti-baff antibodies
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX2017003211A (es) Anticuerpos anti-met y composiciones.

Legal Events

Date Code Title Description
FB Suspension of granting procedure